Kenneth Carson, MD
Hematology & Oncology · Chicago, ILNPI 1720264898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,990 of the $7,618 with a category attached, or 78.6%. 9 manufacturers reported payments, led by Pfizer at 48.7% of the total. 2025 is the largest year on record at $6,130, 4.6 times the $1,322 reported in 2022.
Across 13 payments — averaging $586.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- AstraZeneca$2K
- EMD Serono, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$94
- Kyowa Kirin, Inc.$45
- Gilead$28
- plus $71 from 3 others
Across 4 payments — averaging $27,727 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$103K
- Pfizer$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Consulting fees$5,99079%
- Speaking & faculty fees$1,39018%
- Food & beverage$2383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $3,713 |
| AstraZeneca | 1 | $2,345 |
| EMD Serono, Inc. | 3 | $1,322 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Kyowa Kirin, Inc. | 1 | $45 |
| Gilead | 1 | $28 |
| Beone Medicines USA, Inc. | 1 | $27 |
| Exelixis Inc. | 1 | $23 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,618 in reported general payments places this provider in the 65th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.